MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.

Amgen research and development executive vice-president Jay Bradner said: "Chronic rhinosinusitis with nasal polyps is a recurrent condition often requiring repeat courses of systemic corticosteroids, ...

U.S. drugmaker Amgen (AMGN.O), opens new tab will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said at ...

Robert A. Bradway, president and CEO at Amgen. Headquartered in Iceland, deCODE Genetics has discovered genetic risk factors for dozens of diseases, ranging from cardiovascular disease to cancer.

Novartis shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L.

Drugmaker Amgen to invest $200 million in India site, CEO says U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a ...